Key words in release today FULL development by 2015 for nx 1207. That sounds pretty strong like endorsement of drug and faith in bringing to market at 40% royalty. All that socialized medicine looking for less expensive alternative could prove value of this company faster than anyone expects. Big pharma running trials in Europe (negating one of wrb oncerns) with lower standards for approval and allowed to use us studies. Could see approval in 1 year. Recordati has 400 drug reps and strong move into uro drugs and into us market. How about 40% royalty in us. Market cap to 1 billion real quick. Again market obviously doesn't believe this story or stock would be much higher and I believe wrb presents well the reasons why this stock lags. Still any announcement of US partner sends this stock rapidly higher with show of faith in drug prospects even if extend rights to recordati. Wrb may yet see why patience may be rewarded. Still time to get on board and reap (or loose your but along with the rest of us).
I am not sure #$%$ Partner will boost prices long term; I remember when Recordati came on board, prices shot up for a few days and then settled back. All along people have been saying wait for final enrollment then wait for the reinjection results and nothing happens. I think the catalyst that will move the stock significantly will be the phase three results or a final sale of the company. Good phase two cancer results will also attract attention as that is another unexplored potential niche.